Loading company…
Totient, based in Cambridge, US, develops antibody therapeutics, including a TL1A antibody for inflammatory bowel disease.
Founded in 2017 and headquartered in Cambridge, US, Totient develops biologic therapeutics through an Integrated Drug Creation Platform that uses AI and iterative lab processes. Its proprietary TL1A antibody targets Inflammatory Bowel Disease, and the platform aims to take a drug from concept to clinical trials in about 24 months. It works with pharmaceutical companies and research institutions in North America and Europe through collaborations and milestone-based payments. AbSci, LLC acquired Totient in June 2021. The company raised USD 10.00 mn in its June 2021 Seed round from Kaitai Capital and Mission BioCapital. Deniz Kural is CEO and founder.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in